Detalhe da pesquisa
1.
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.
BMC Pulm Med
; 23(1): 482, 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031067
2.
ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
BMC Pulm Med
; 22(1): 483, 2022 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36539782
3.
Hypoxia differently regulates the proportion of ALDHhi cells in lung squamous carcinoma H520 and adenocarcinoma A549 cells via the Wnt/ß-catenin pathway.
Thorac Cancer
; 2024 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38736300
4.
Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Heliyon
; 9(8): e17400, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37520982
5.
CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma.
Front Oncol
; 12: 867788, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35574406
6.
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Front Oncol
; 12: 978069, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36330494
7.
Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Front Immunol
; 13: 1030969, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426352
8.
Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
Thorac Cancer
; 12(22): 3053-3061, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34617400